Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Profound Medical Corp (TSX:PRN)

7.630 -0.110 (-1.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Profound Medical Corp

< Previous 1 2 3 Next >
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Second Quarter 2024 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Annual General Meeting of Shareholders Voting Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
From Profound Medical Corp.
Via GlobeNewswire
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Non-Brokered Private Placement
From Profound Medical Corp.
Via GlobeNewswire
BioMedNewsBreaks – Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) Announces Pricing of US$20M Public Offering
Via Investor Brand Network
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Proposed Public Offering of Common Shares
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in the Stifel 2023 Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Third Quarter 2023 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical 2023 Virtual Analyst & Investor Day Agenda
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost
The first of the TULSA AI modules, Thermal Boost enables predictable, customized ablation at the prostate capsule 
From Profound Medical Corp.
Via GlobeNewswire
Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces At-the-Market Offering of up to US$30,000,000
From Profound Medical Corp.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.